Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31292655 | 0.83 | APLNR (0.46) | KMT2ASMN1; SMN2GAAMEN1TSHR | |
| SCHEMBL896384 | 0.82 | MEN1 (0.47) | KMT2ASMN1; SMN2GAAMEN1TSHR | |
| SCHEMBL27669113 | 0.81 | MEN1 (0.46) | KMT2ASMN1; SMN2GAAMEN1TSHR | |
| SCHEMBL15415157 | 0.80 | TSHR (0.38) | KMT2ASMN1; SMN2GAAMEN1TSHR | |
| SCHEMBL30563829 | 0.80 | ALDH1A1 (0.41) | KMT2ASMN1; SMN2ALDH1A1HPGDKDM4E | |
| SCHEMBL2184519 | 0.79 | SMN1; SMN2 (0.64) | KMT2ASMN1; SMN2GAAMEN1TSHR | |
| SCHEMBL27876362 | 0.78 | SMN1; SMN2 (0.44) | KMT2ASMN1; SMN2GAAMEN1TSHR | |
| SCHEMBL15416324 | 0.78 | TSHR (0.37) | KMT2ASMN1; SMN2GAAMEN1TSHR | |
| SCHEMBL22092259 | 0.77 | LMNA (0.45) | KMT2ASMN1; SMN2GAAMEN1TSHR | |
| SCHEMBL17765202 | 0.76 | POLB (0.54) | KMT2ASMN1; SMN2GAAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11492345-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| CN-105814054-B | Condensed imidazole and pyrazole derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-09-25 | — | — | CN | disclosed |
| WO-2018148745-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES , INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| CN-105814055-B | As the condensed imidazole and pyrazole derivatives of TNF active regulators | UCB生物制药私人有限公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-105814055-A | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814054-A | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| US-5973156-A | Piperidine and tetrahydropyridine derivatives | MERCK SHARP & DOME LTD. (GB) | 1999-10-26 | — | — | US | disclosed |
| EP-0861245-A1 | PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997019073-A1 | PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | KMT2A 1112/4885SMN1; SMN2 334/4885GAA 832/4885 |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | KMT2A 1112/4885SMN1; SMN2 334/4885GAA 832/4885 |
| US-11492345-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN1B | KMT2A 1112/4885SMN1; SMN2 334/4885GAA 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.